Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $224.14 and traded as low as $199.40. Genmab A/S shares last traded at $199.40, with a volume of 15 shares traded.
Genmab A/S Stock Performance
The company has a market cap of $13.80 billion, a PE ratio of 11.92 and a beta of 1.08. The stock has a 50 day moving average of $211.21 and a 200-day moving average of $223.20.
Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last issued its earnings results on Wednesday, February 12th. The company reported $5.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.
About Genmab A/S
(
Get Free Report)
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Further Reading
Before you consider Genmab A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.
While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
